SCHEMBL4254071

SCHEMBL4254071

Cc1ncc(-c2ccnc(Nc3ccc(N4CCN(C(=O)[C@@H](C)O)CC4)cn3)n2)n1C(C)C

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 16/20 0.81
KCNH2 Q12809 7/20 0.58
CDK1 P06493 8/20 0.56
CDK4 P11802 4/20 0.53
CCNB1 P14635 4/20 0.53
CCND1 P24385 4/20 0.53
CDK6 Q00534 4/20 0.53
CCNT1 O60563 3/20 0.53
CCNA2 P20248 3/20 0.53
CCND3 P30281 3/20 0.53
CDK7 P50613 3/20 0.53
CDK9 P50750 3/20 0.53
CCNH P51946 3/20 0.53
CSNK2A2 P19784 1/20 0.49
CCNE1 P24864 1/20 0.49
MAPK8 P45983 1/20 0.49
MAPK9 P45984 1/20 0.49
CSNK1A1 P48729 1/20 0.49
CSNK1D P48730 1/20 0.49
GSK3A P49840 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4254074 1.00 CDK2 (0.81) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL27701541 0.85 CDK2 (0.62) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL4254089 0.84 CDK4 (0.68) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL3549598 0.80 CDK2 (0.83) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL3548656 0.78 CDK2 (1.00) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL4246292 0.78 CDK2 (0.67) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL3551129 0.78 CDK2 (0.85) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL1447857 0.77 CDK2 (0.79) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL4246771 0.77 CDK4 (0.54) CDK2KCNH2CDK1CDK4CCNB1
SCHEMBL3558916 0.76 CDK2 (1.00) CDK2KCNH2CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233928-A1 IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233928-A1 IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION MKI67, TYMP, PCNA CDK2 23/4885KCNH2 4185/4885CDK1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.